Catalog No.S1380 Synonyms: ABT-378
Molecular Weight(MW): 628.8
Lopinavir is a potent HIV protease inhibitor with Ki of 1.3 pM in a cell-free assay.
Cited by 6 Publications
2 Customer Reviews
Sodium butyrate and lopinavir treatment represent pharmacological aging models that reproduce key properties of cellular aging. LLC-PK1 cells were incubated with vehicle (controls), sodium butyrate or lopinavir and assessed for different indicators of aging. (A) The number of cells that scored positive for SA-β-galactosidase activity increased significantly upon treatment with sodium butyrate or lopinavir. Data are shown for three independent experiments as average + SEM. Results were normalized to controls and depicted as arbitrary units (AU). (B) Sodium butyrate and lopinavir increase cell size, cause nuclear dysmorphy, reduce cell proliferation, while lamin A becomes more abundant. Confocal images were acquired for 5-ethynyl-2′-deoxyuridine (EdU) and lamin A (Materials and methods). Representative images are shown for control and treated samples. Scale bar, 20 μm. (C) Nuclear fluorescence was quantified for EdU and lamin A for at least three independent experiments. Pixel intensities were measured for > 100 cells for each experiment per condition. NaBu, sodium butyrate, D, DMSO, Lopi, lopinavir. **, p < 0.01; ***, p < 0.001.
Biochim Biophys Acta, 2017, 1864(3):475-486. Lopinavir purchased from Selleck.
Low-micromolar amounts of chloroquine, chlorpromazine, loperamide, and lopinavir inhibit MERS-CoV-induced cytopathology. Huh7 cells in 96-well plates were infected with MERS-CoV isolate EMC/2012 (MOI, 0.005) in the presence of 0 to 20 uM LPV. Cells were incubated for 2 days, and cell viability was monitored using an MTS assay. In addition, the potential toxicity of compound treatment only was monitored in parallel mock-infected Huh7 cell cultures. Graphs show the results (averages and standard deviations [SD]) of a representative experiment that was performed in quadruplicate. All experiments were repeated at least twice. For each compound, the calculated EC50, CC50, and SI values are given.
Antimicrob Agents Chemother 2014 58(8), 4875-84. Lopinavir purchased from Selleck.
Purity & Quality Control
Choose Selective HIV Protease Inhibitors
|Description||Lopinavir is a potent HIV protease inhibitor with Ki of 1.3 pM in a cell-free assay.|
Lopinavir binds to mutant HIV protease (V82A, V82F and V82T) with Ki of 4.9 pM, 3.7 pM and 3.6 pM, respectively. Lopinavir inhibits 93% of wild-type HIV protease activity at 0.5 nM. Lopinavir inhibits HIV protease activity in the absence and presence of 50% HS with EC50 of 17 nM and 102 nM, respectively, in MT4 cells.  Lopinavir is converted to several metabolites in an NADPH-dependent manner in liver microsomes with the primary metabolites M-3 and M-4.  Lopinavir is a potent inhibitor of Rh123 efflux in Caco-2 monolayers with IC50 of 1.7 mM. Lopinavir exposure (72 hours) in LS 180V cells reduces the content of intracellular Rh123. Lopinavir induces P-glycoprotein immunoreactive protein and messenger RNA levels in LS 180V cells.  Lopinavir inhibits subtype C clone C6 with IC50 of 9.4 nM.  Lopinavir inhibits CYP3A with IC50 of 7.3 mM in human liver microsomes, while produces negligible or weak inhibition of human CYP1A2, 2B6, 2C9, 2C19 and 2D6. 
|In vivo||Lopinavir (10 mg/kg, orally) results in Cmax of 0.8 μg/mL and oral bioavailability of 25% in rats. |
-  Sham HL, et al. Antimicrob Agents Chemother, 1998, 42(12), 3218-3224.
-  Kumar GN, et al. Drug Metab Dispos, 1999, 27(1), 86-91.
-  Vishnuvardhan D, et al. AIDS, 2003, 17(7), 1092-1094.
|In vitro||DMSO||126 mg/mL (200.38 mM)|
|Ethanol||126 mg/mL (200.38 mM)|
|In vivo||Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02845843||Recruiting||Middle East Respiratory Syndrome Coronavirus (MERS-CoV)||King Abdullah International Medical Research Center||July 2016||Phase 2|Phase 3|
|NCT02671383||Recruiting||HIV Infections||Willem Daniel Francois Venter|Medical Research Council, South Africa|University of Witwatersrand, South Africa||July 2016||Phase 3|
|NCT02712801||Recruiting||HIV/AIDS and Infections||National Center for Women and Childrens Health, China CDC|National Center for AIDS/STD Control and Prevention, China CDC|Maternal and Child Health Hospital of Yunan Province|Maternal and Child Health Hospital of Sichuan Province|Maternal and Child Health Hospital of Guangxi Province|Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region|Guangdong Provincial Maternal and Child Health Hospital||April 2016||Phase 4|
|NCT02150993||Recruiting||HIV-2 Infection||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||January 2016||Phase 2|Phase 3|
|NCT01700790||Recruiting||AIDS|Tuberculosis||University of Miami|Oswaldo Cruz Foundation||January 2016||Phase 4|
|NCT02581202||Active, not recruiting||HIV-1 Infection||AbbVie||December 2015||--|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.